All times shown are PDT (GMT-7) (San Francisco)
Satellite Channel 2
Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Diverse and promising HIV vaccines candidates are in various stages of development and exciting results from vaccine efficacy and passive immunization trials are expected in the coming years. The vaccine field remains hopeful and determined - even with the necessary shift in attention to developing SARS-CoV-2 control measures. Communicating the wealth and breadth of ongoing research, and the steadfast commitments of funders, researchers, product developers and communities to find a vaccine remains critically important. Co-sponsored by the Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC, this satellite will showcase current HIV vaccine research and development.
Full Session Recording
Words of welcome
The challenges of developing a vaccine: Compare and contrast HIV & SARS-CoV-2
Panel Discussion
- Mitchell Warren, AVAC
- Glenda Gray, South African Medical Research Council
- Luc Debruyne, CEPI
- Martin Friede, WHO
- Robin Shattock, Imperial College London
- Maureen Luba, AVAC
- Roger Tatoud, International Aids Society
- Nina Russell, Bill and Melinda Gates Foundation
- Sanjay Gurunathan, Sanofi Pasteur
- Paul Stoffels, Johnson and Johnson